Prognostic factors and a Cox proportional hazards model for survival in primary liver cancer
Authors:
- Bei LiuBLBei Liu
- Daojuan LiDLDaojuan Li
- Yanyu LiuYLYanyu Liu
- Zining HeZHZining He
- Yutong HeYHYutong He
Open Access
- 9 November 2026
- journal article
- Published by OAE Publishing Inc. in Hepatoma Research
- Vol. 12
Abstract
Aim: Accurate prognostic assessment using biochemical indices is essential for personalized management of primary liver cancer in community-level hospitals. This study aimed to construct and validate a Cox regression-based nomogram integrating these indices with clinicopathological data to predict overall survival (OS). Methods: In this retrospective study, 1,124 patients with primary liver cancer were randomly allocated in a 7:3 proportion into training and validation cohorts. Univariable and multivariate Cox proportional hazards analyses were performed to identify independent prognostic factors and establish a nomogram for predicting OS at 1, 3, and 5 years. The model’s discrimination was assessed via the concordance index (C-index) and time-dependent receiver operating characteristic (ROC) curves. Furthermore, calibration curves and decision curve analysis (DCA) were utilized to evaluate predictive agreement and clinical utility. Results: Multivariate analysis identified an elevated aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio, high alpha-fetoprotein (AFP ≥ 400 ng/mL), reduced body mass index (BMI < 18.5 kg/m2), and advanced tumor-node-metastasis (TNM) stage as independent adverse predictors for OS, while surgical resection and hepatitis history favored survival. The nomogram showed moderate discrimination, yielding C-indices of 0.678 (training cohort) and 0.659 (validation cohort), with corresponding areas under the curve (AUCs) for years 1, 3, and 5 of 0.725, 0.733, and 0.779 in the training cohort and 0.700, 0.718, and 0.750 in the validation cohort. Furthermore, the model effectively stratified patients into distinct prognostic risk groups (log-rank test P < 0.001). Conclusion: This nomogram may assist clinicians in risk stratification and survival estimation for primary liver cancer patients in primary-level healthcare settings.Keywords
This publication has 59 references indexed in Scilit:
- Advancing liver cancer diagnosis and treatment with multi-omics approaches: a systematic reviewDiscover Oncology, 2025
- Heterogeneity in prognosis for early-stage hepatocellular carcinoma after hepatectomy: A multicenter analysis of 4,623 patients across five major staging systemsEuropean Journal of Surgical Oncology, 2025
- Robotic vs laparoscopic resection for hepatocellular carcinoma: multicentric propensity-score matched analysis of surgical and oncologic outcomes in 647 patientsUpdates in Surgery, 2025
- Identification of Patients with Early-Stage Hepatocellular Carcinoma Benefiting from Neoadjuvant Chemotherapy—A SEER-Based StudyJournal of Gastrointestinal Cancer, 2025
- A comprehensive comparison of two commonly used BMI thresholds for non-communicable diseases and multimorbidity in the Chinese populationClinical Nutrition, 2025
- Benefits of entecavir therapy in HBV-related hepatocellular carcinoma patients with compensated cirrhosis after hepatectomy: A ten-year retrospective cohort studyEuropean Journal of Surgical Oncology, 2025
- A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapyCancer Immunology, Immunotherapy, 2024
- Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2021
- Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier StagePathology and Oncology Research, 2019
- HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K/AKT signal pathwayInternational Journal of Cancer, 2017